Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
4217381 | Thoracic Surgery Clinics | 2008 | 9 Pages |
Abstract
Lymph node involvement is the most important factor affecting the prognosis and treatment of patients with potentially resectable NSCLC. Radiographic imaging is inadequate to ascertain lymph node involvement. Currently, lymph nodes are assessed pathologically using conventional histologic techniques; however, lymph node micrometastases may be missed, leading to inaccurate staging and suboptimal treatment. Assessment of occult involvement using antibody expression improves the sensitivity of lymph node analysis, and more advanced techniques, using molecular biologic methods, may further improve lymph node staging. Optimizing outcomes of patients with lung cancer depends on accurate lymph node staging, and the development of the strategies that improve the assessment of lymph node micrometastases will be beneficial.
Related Topics
Health Sciences
Medicine and Dentistry
Pulmonary and Respiratory Medicine
Authors
Loretta MD, Thomas A. MD,